ABOS ABOS
Company Profile ↓Company Overview
ABOS (ABOS) is a publicly traded company listed on with a market capitalization of $135.69M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +68.42% |
| 6 Months: | -12.84% |
| 3 Months: | -11.11% |
| 1 Month: | -12.84% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)46.94 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 33.5% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 30.37M | 41.75M | 26.51M | 25.20M | 21.15M |
| Operating Income | -2.04M | -2.49M | -3.79M | -3.44M | -3.94M | -9.21M | -10.41M | -11.37M | -13.13M | -13.48M | -16.04M | -17.77M | -24.38M | -32.27M | -30.37M | -41.75M | -26.51M | -25.20M | -21.15M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -27.73M | -39.86M | -25.34M | -24.01M | -19.62M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.02M | 1.05M | 1.07M | 1.09M | 1.07M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -28.80M | -40.95M | -26.45M | -25.14M | -20.74M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -2.04M | -2.49M | -27.00M | -61.36M | -3.90M | -9.13M | -10.15M | -10.71M | -11.31M | -11.61M | -12.96M | -14.87M | -20.54M | -29.77M | -28.80M | -40.95M | -26.45M | -25.14M | -20.74M |
| Diluted EPS | - | - | - | -141.93 | -0.10 | -0.23 | -0.25 | -0.26 | -0.28 | -0.28 | -0.24 | -0.25 | -0.34 | -0.50 | -0.48 | -0.68 | -0.44 | - | -0.33 |
| R&D Expense | 1.93M | 2.99M | 2.58M | 2.25M | 1.80M | 5.99M | 7.32M | 8.31M | 8.71M | 9.13M | 11.18M | 12.45M | 19.53M | 27.25M | 25.27M | 37.12M | 21.97M | - | 16.48M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 45.24M | 61.14M | 114.02M | 123.83M |
| Operating Income | -7.91M | - | -45.24M | -61.14M | -114.02M | -123.83M |
| EBITDA | - | - | -42.69M | -51.61M | -98.08M | -116.93M |
| Interest Expense | - | - | 0 | 581.00K | 4.07M | 4.22M |
| Pretax Income | - | - | -42.86M | -52.37M | -102.33M | -121.33M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | -7.33M | - | -42.86M | -52.37M | -102.33M | -121.33M |
| Diluted EPS | - | - | -1.06 | -1.08 | -1.71 | -2.00 |
| R&D Expense | 8.00M | 12.30M | 32.36M | 42.32M | 93.80M | 104.89M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 44.43M | - | 196.59M | 310.12M | 238.99M | 122.83M |
| Current Assets | - | - | - | 180.33M | 246.62M | 178.31M | 122.25M |
| Cash & Equivalents | 6.55M | 43.78M | - | 130.10M | 66.89M | 35.63M | 53.99M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | 0 | 225.00K | 345.00K | 625.00K |
| Total Liabilities | - | 6.37M | - | 7.81M | 43.15M | 57.18M | 52.40M |
| Current Liabilities | - | - | - | 7.81M | 12.97M | 27.61M | 30.01M |
| Long Term Debt | - | - | - | - | 27.34M | 28.45M | 22.40M |
| Total Debt | - | - | - | 105.00K | 28.49M | 28.73M | 31.31M |
| Total Equity | -11.42M | -18.59M | - | 188.78M | 266.97M | 181.82M | 70.43M |
| Shares Outstanding | - | - | - | 41.03M | 57.91M | 60.09M | 60.58M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.45M | - | -35.15M | -43.06M | -86.22M | -115.54M |
| Investing Cash Flow | - | - | 39.19M | -171.67M | 48.03M | 133.93M |
| Financing Cash Flow | 44.67M | - | 3.91M | 151.75M | 6.93M | -34.00K |
| Capital Expenditure | - | - | -161.00K | -21.00K | -16.00K | -88.00K |
| Free Cash Flow | - | - | -35.31M | -43.09M | -86.23M | -115.63M |
| Net Change in Cash | - | - | 7.94M | -62.98M | -31.26M | 18.36M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 39.4% | - | -22.7% | -19.6% | -56.3% | -172.3% |
| ROCE % | - | - | -24.0% | -20.6% | -53.9% | -133.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ABOS
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026
NEWTON, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligom…
All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy
Acumen Pharmaceuticals (ABOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year?
Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Amarin (AMRN) have performed compared to their sector so far this year.
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026
EBD™ bispecific antibodies targeting both AβOs and hTfR showed improved brain penetration compared to the native anti-AβO antibodies, which may enable administration with a low-volume delivery device and reduce the delivered dose required f…
Acumen Pharmaceuticals and Unlearn Collaborate to Explore Analyses of Alzheimer's Disease Clinical Programs
SAN FRANCISCO, CA AND NEWTON, MA / ACCESS Newswire / July 9, 2026 / Unlearn, a pioneer of AI-powered solutions for clinical development, today announced a collaboration with Acumen Pharmaceuticals (Acumen), a clinical-stage biopharmaceutica…
Acumen Pharmaceuticals Inc (ABOS) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...
Acumen Pharmaceuticals Inc (ABOS) showcases promising developments in Alzheimer's treatment and cost management, despite reporting a net loss for the quarter.
ABOS — Frequently Asked Questions
What is the current share price of ABOS?
As of 2026-08-05 17:25 PDT, ABOS trades at $2.24 on NASDAQ/NYSE. Its 52-week range is $1.23 to $3.37.
What is the market capitalisation of ABOS?
ABOS has a market capitalisation of $135.69M on NASDAQ/NYSE.
What is the P/E ratio of ABOS?
ABOS trades at a trailing price-to-earnings (P/E) ratio of -1.12. Its price-to-book (P/B) ratio is 1.93.
Is ABOS a good stock to buy?
This page provides a data-driven analysis of ABOS, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.